RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VIVA Biotech Holdings Stock

VIVA Biotech Holdings EBIT 2024

VIVA Biotech Holdings EBIT

401.91 M CNY

Ticker

1873.HK

ISIN

KYG9390W1015

WKN

A2PH5Q

In 2024, VIVA Biotech Holdings's EBIT was 401.91 M CNY, a 71.24% increase from the 234.71 M CNY EBIT recorded in the previous year.

The VIVA Biotech Holdings EBIT history

YEAREBIT (undefined CNY)
2025e487.27
2024e401.91
2023234.71
2022295.38
2021260.11
202089.5
201960.14
201854.56
201757.43
201629.41

VIVA Biotech Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into VIVA Biotech Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by VIVA Biotech Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects VIVA Biotech Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of VIVA Biotech Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into VIVA Biotech Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing VIVA Biotech Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on VIVA Biotech Holdings’s growth potential.

VIVA Biotech Holdings Revenue, EBIT and net profit per share

DateVIVA Biotech Holdings RevenueVIVA Biotech Holdings EBITVIVA Biotech Holdings Net Income
2025e3.43 B undefined487.27 M undefined519.94 M undefined
2024e3.03 B undefined401.91 M undefined439.11 M undefined
20232.16 B undefined234.71 M undefined-116.11 M undefined
20222.38 B undefined295.38 M undefined-528.48 M undefined
20212.1 B undefined260.11 M undefined287.55 M undefined
2020696.96 M undefined89.5 M undefined-386.88 M undefined
2019323.06 M undefined60.14 M undefined265.87 M undefined
2018210.03 M undefined54.56 M undefined90.55 M undefined
2017148.25 M undefined57.43 M undefined76.26 M undefined
201696.49 M undefined29.41 M undefined24.47 M undefined

VIVA Biotech Holdings stock margins

The VIVA Biotech Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VIVA Biotech Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VIVA Biotech Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the VIVA Biotech Holdings's sales revenue. A higher gross margin percentage indicates that the VIVA Biotech Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the VIVA Biotech Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the VIVA Biotech Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the VIVA Biotech Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the VIVA Biotech Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the VIVA Biotech Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

VIVA Biotech Holdings Margin History

VIVA Biotech Holdings Gross marginVIVA Biotech Holdings Profit marginVIVA Biotech Holdings EBIT marginVIVA Biotech Holdings Profit margin
2025e34.26 %14.21 %15.17 %
2024e34.26 %13.28 %14.51 %
202334.26 %10.89 %-5.39 %
202234.28 %12.41 %-22.21 %
202130.94 %12.36 %13.67 %
202043.74 %12.84 %-55.51 %
201948.25 %18.61 %82.3 %
201850.21 %25.98 %43.11 %
201758.14 %38.74 %51.44 %
201656.11 %30.48 %25.36 %

VIVA Biotech Holdings Aktienanalyse

What does VIVA Biotech Holdings do?

VIVA Biotech Holdings is a Chinese company specializing in the development of pharmaceuticals. It was listed on the Hong Kong Stock Exchange in 2018 and is headquartered in Shanghai. The company started as a small start-up in 2013 but has quickly become one of the industry leaders in pharmaceutical discovery and development. VIVA Biotech Holdings' business model revolves around creating a shared ecosystem for biotechnology start-ups and their customers. The company offers a wide range of services, including target molecule identification and validation, drug candidate optimization, and speeding up the timeline for clinical trials and commercialization. One key aspect of VIVA Biotech Holdings' business model is its VIVA Accelerator programs, which support and foster promising early-stage biotechnology start-ups. These programs provide start-ups with access to state-of-the-art facilities, expert advice, and funding opportunities. The company also operates several divisions focused on the discovery and development of new pharmaceuticals. These divisions include drug candidate synthesis, screening platforms for identifying drug candidates, and structural elucidation of proteins and other molecules. A major focus of VIVA Biotech Holdings is the development of cancer treatments. The company has developed a wide range of drug candidates that specifically target and destroy cancer cells. This includes both small molecules and biological drugs. In addition to cancer research, VIVA Biotech Holdings is also involved in the discovery and development of drugs for other diseases such as inflammatory and metabolic disorders. The company works closely with its customers and partners to develop targeted treatment options. Overall, VIVA Biotech Holdings has achieved an impressive track record in drug discovery and development in recent years. The company has developed a wide range of drug candidates at various stages of clinical development that have the potential to revolutionize the treatment of cancer and other diseases. As a company, VIVA Biotech Holdings is also committed to promoting the biotechnology sector and supporting start-ups and young companies. It is an important player in the Chinese biotech industry and an emerging company in the global pharmaceutical development market. VIVA Biotech Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing VIVA Biotech Holdings's EBIT

VIVA Biotech Holdings's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of VIVA Biotech Holdings's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

VIVA Biotech Holdings's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in VIVA Biotech Holdings’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about VIVA Biotech Holdings stock

How much did VIVA Biotech Holdings achieve in EBIT for the current year?

In the current year, VIVA Biotech Holdings has achieved an EBIT of 401.91 M CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company VIVA Biotech Holdings.

How has the EBIT of VIVA Biotech Holdings developed in recent years?

The EBIT of VIVA Biotech Holdings has increased by 71.238% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company VIVA Biotech Holdings?

The EBIT of VIVA Biotech Holdings is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does VIVA Biotech Holdings pay?

Over the past 12 months, VIVA Biotech Holdings paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 1.15 %. For the coming 12 months, VIVA Biotech Holdings is expected to pay a dividend of 0.01 CNY.

What is the dividend yield of VIVA Biotech Holdings?

The current dividend yield of VIVA Biotech Holdings is 1.15 %.

When does VIVA Biotech Holdings pay dividends?

VIVA Biotech Holdings pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of VIVA Biotech Holdings?

VIVA Biotech Holdings paid dividends every year for the past 2 years.

What is the dividend of VIVA Biotech Holdings?

For the upcoming 12 months, dividends amounting to 0.01 CNY are expected. This corresponds to a dividend yield of 1.38 %.

In which sector is VIVA Biotech Holdings located?

VIVA Biotech Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIVA Biotech Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIVA Biotech Holdings from 7/9/2021 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2021.

When did VIVA Biotech Holdings pay the last dividend?

The last dividend was paid out on 7/9/2021.

What was the dividend of VIVA Biotech Holdings in the year 2023?

In the year 2023, VIVA Biotech Holdings distributed 0 CNY as dividends.

In which currency does VIVA Biotech Holdings pay out the dividend?

The dividends of VIVA Biotech Holdings are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIVA Biotech Holdings

Our stock analysis for VIVA Biotech Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIVA Biotech Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.